Oxidative modification of lipoproteins: Mechanisms, role in inflammation and potential clinical applications in cardiovascular disease

Current Pharmaceutical Design

Volumn 17, Issue 1, 2011, Pages 27-37

  Tsimikas, Sotirios ^a   Miller, Yury I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Biomarkers; Imaging; Inflammation; Lipoproteins; Oxidation; Phospholipids

Indexed keywords

APOLIPOPROTEIN B100; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPROTEIN; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TRANSITION ELEMENT;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CELL SURVIVAL; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PHOSPHOLIPIDS;

EID: 79953731953     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161211795049831     Document Type: Article

References (146)

1. Libby P, Ridker PM, Hansson GrK. Inflammation in Atherosclerosis: From Pathophysiology to Practice. J Am Coll Cardiol 2009; 54(23): 2129-38.
2. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002; 22(10): 1649-54.
3. Gotto AM, Jr., Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol 1986; 128: 3-41.
4. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29(4): 431-8.
5. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that Increase its atherogenicity. New Engl J Med 1989; 320: 915-24.
6. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11(3-4): 93-102.
7. Miller YI, Tsimikas S. In: Ballantine C, Ed. Clinical Lipidology: a Companion to Braunwald's Heart Disease. USA: Elsevier Saunders 2009; pp. 93-110.
8. Stoletov K, Fang L, Choi SH, et al. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholes terolemic zebrafish. Circ Res 2009; 104: 952-60.
9. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8(11): 1218-26.
10. Chou MY, Fogelstrand L, Hartvigsen K, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119(5): 1335-49.
11. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81(12): 3883-7.
12. Esterbauer H, Jurgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28(5): 495-509.
13. Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 1993; 91(2): 668-76.
14. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13(4): 341-90.
15. Sigari F, Lee C, Witztum JL, Reaven PD. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler Thromb Vasc Biol 1997; 17(12): 3639-45.
16. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85(4): 1260-6.
17. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278(3): 1561-8.
18. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996; 16(7): 831-42.
19. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001; 11(3-4): 142-7.
20. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003; 14(5): 437-45.
21. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25(6): 1213-9.
22. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinase dependent activation of NADPH oxidase 2. Circ Res 2009; 104(2): 210-8.
23. Choi S-H, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104: 1355-63.
24. Miller YI, Felikman Y, Shaklai N. The involvement of low-density lipoprotein in hemin transport potentiates peroxidative damage. Biochim Biophys Acta 1995; 1272(2): 119-27.
25. Miller YI, Shaklai N. Kinetics of hemin distribution in plasma reveals its role in lipoprotein oxidation. Biochim Biophys Acta 1999; 1454(2): 153-64.
26. Ziouzenkova O, Asatryan L, Akmal M, et al. Oxidative cross linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999; 274(27): 18916-24.
27. Miller YI, Felikman Y, Shaklai N. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch Biochem Biophys 1996; 326(2): 252-60.
28. Ziouzenkova O, Asatryan L, Tetta C, Wratten ML, Hwang J, Sevanian A. Oxidative stress during ex vivo hemodialysis of blood is decreased by a novel hemolipodialysis procedure utilizing antioxidants. Free Radic Biol Med 2002; 33(2): 248-58.
29. Sevanian A, Asatryan L. LDL modification during hemodialysis. Markers for oxidative stress. Contrib Nephrol 2002; (137): 386-95.
30. Watanabe J, Chou KJ, Liao JC, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice: a novel biomarker of atherosclerosis. J Biol Chem 2007; 282(32): 23698-707.
31. Watanabe J, Grijalva V, Hama S, et al. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009; 284(27): 18292-301.
32. Miller YI, Altamentova SM, Shaklai N. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin 248. Biochemistry 1997; 36(40): 12189-98.
33. Philippidis P, Mason JC, Evans BJ, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: anti-inflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 2004; 94(1): 119-26.
34. Asleh R, Marsh S, Shilkrut M, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003; 92(11): 1193-200.
35. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype and diabetes-dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res 2005; 96(4): 435-41.
36. Burbea Z, Nakhoul F, Zoabi R, et al. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem 2004; 41(Pt 6): 469-73.
37. Levy AP, Hochberg I, Jablonski K, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 2002; 40(11): 1984-90.
38. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003; 26(9): 2628-31.
39. Levy AP, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007; 27(1): 134-40.
40. Moreno PR, Purushothaman KR, Purushothaman M, et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008; 52(13): 1049-51.
41. Milman U, Blum S, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008; 28(2): 341-7.
42. Blum S, Vardi M, Brown JB, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 2010; 11(5): 675-84.
43. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877-84.
44. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104(4): 503-16.
45. Cyrus T, Witztum JL, Rader DJ, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999; 103(11): 1597-604.
46. George J, Afek A, Shaish A, et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 2001; 104(14): 1646-50.
47. Cyrus T, Pratico D, Zhao L, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001; 103(18): 2277-82.
48. Reilly KB, Srinivasan S, Hatley ME, et al. 12/15-lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 2004; 279(10): 9440-50.
49. Huo Y, Zhao L, Hyman MC, et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein Edeficient mice. Circulation 2004; 110(14): 2024-31.
50. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992; 1128(2-3): 117-31.
51. Liavonchanka A, Feussner I. Lipoxygenases: Occurrence, functions and catalysis. J Plant Physiol 2006; 163(3): 348-57.
52. Belkner J, Stender H, Kuhn H. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J Biol Chem 1998; 273(36): 23225-32.
53. Ezaki M, Witztum JL, Steinberg D. Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. J Lipid Res 1995; 36(9): 1996-2004.
54. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized LDL. J Biol Chem 2008; 283(16): 10241-51.
55. Takahashi Y, Zhu H, Xu W, et al. Selective uptake and efflux of cholesteryl linoleate in LDL by macrophages expressing 12/15-lipoxygenase. Biochem Biophys Res Commun 2005; 338(1): 128-35.
56. Zhu H, Takahashi Y, Xu W, et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem 2003; 278(15): 13350-55.
57. Miller YI, Chang MK, Funk CD, Feramisco JR, Witztum JL. 12/15-Lipoxygenase translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic cells. J Biol Chem 2001; 276: 19431-9.
58. Letters JM, Witting PK, Christison JK, Eriksson AW, Pettersson K, Stocker R. Time-dependent changes to lipids and antioxidants in plasma and aortas of apolipoprotein E knockout mice. J Lipid Res 1999; 40(6): 1104-12.
59. Upston JM, Niu X, Brown AJ, et al. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 2002; 160(2): 701-10.
60. Leitinger N. Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 2003; 24(4-5): 239-50.
61. Poeckel D, Zemski Berry KA, Murphy RC, Funk CD. Dual 12/15-and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in APOE knockout mice. J Biol Chem 2009; 284(31): 21077-89.
62. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22(10): 3595-606.
63. Shen J, Herderick E, Cornhill JF, et al. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996; 98(10): 2201-8.
64. McCaskie PA, Beilby JP, Hung J, et al. 15-Lipoxygenase gene variants are associated with carotid plaque but not carotid intimamedia thickness. Hum Genet 2008; 123(5): 445-53.
65. McGeachie M, Ramoni RL, Mychaleckyj JC, et al. Integrative predictive model of coronary artery calcification in atherosclerosis. Circulation 2009; 120(24): 2448-54.
66. Fairfax BP, Vannberg F, Radhakrishnan J, et al. An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. Hum Mol Genet 2009; ddp530.
67. Hersberger M, Muller M, Marti-Jaun J, et al. No association of two functional polymorphisms in human ALOX15 with myocardial infarction. Atherosclerosis 2009; 205(1): 192-6.
68. Lemaitre RN, Rice K, Marciante K, et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 2009; 204(2): e58-63.
69. Assimes TL, Knowles JW, Priest JR, et al. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis 2008; 198(1): 136-44.
70. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105(8): 1095-108.
71. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13(10): 1176-84.
72. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
73. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional highdensity lipoprotein by myeloperoxidase. Trends Cardiovasc Med 2005; 15(6): 212-9.
74. Shao B, Oda MN, Bergt C, et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 2006; 281(14): 9001-4.
75. Noguchi N, Nakano K, Aratani Y, Koyama H, Kodama T, Niki E. Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. J Biochem (Tokyo) 2000; 127(6): 971-6.
76. Brennan ML, Anderson MM, Shih DM, et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001; 107(4): 419-30.
77. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005; 111(21): 2798-804.
78. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001; 142(2): 336-9.
79. Makela R, Karhunen PJ, Kunnas TA, et al. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab Invest 2003; 83(7): 919-25.
80. Barry-Lane PA, Patterson C, van der Merwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE-/mice. J Clin Invest 2001; 108(10): 1513-22.
81. Hsich E, Segal BH, Pagano PJ, et al. Vascular effects following homozygous disruption of p47phox: an essential component of NADPH oxidase. Circulation 2000; 101(11): 1234-6.
82. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000; 20(6): 1529-35.
83. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24(1): 23-8.
84. Detmers PA, Hernandez M, Mudgett J, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 2000; 165(6): 3430-5.
85. Ihrig M, Dangler CA, Fox JG. Mice lacking inducible nitric oxide synthase develop spontaneous hypercholesterolaemia and aortic atheromas. Atherosclerosis 2001; 156(1): 103-7.
86. Shi W, Wang X, Shih DM, Laubach VE, Navab M, Lusis AJ. Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation 2002; 105(17): 2078-82.
87. Witztum JL. You are right too! J Clin Invest 2005; 115(8): 2072-5.
88. Webb NR, Moore KJ. Macrophage-derived foam cells in atherosclerosis: lessons from murine models and implications for therapy. Curr Drug Targets 2007; 8(12): 1249-63.
89. Miller YI, Choi SH, Fang L, Harkewicz R. Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc Med 2009; 7: 227-32.
90. Miller YI, Choi S-H, Fang L, Tsimikas S. Lipoprotein modification and macrophage uptake: Role of pathologic cholesterol transport in atherogenesis. Subcell Biochem 2010; 51: 229-51.
91. Benz DJ, Mol M, Ezaki M, et al. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J Biol Chem 1995; 270(10): 5191-7.
92. Miller YI, Worrall DS, Funk CD, Feramisco JR, Witztum JL. Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell 2003; 14(10): 4196-206.
93. Boullier A, Li Y, Quehenberger O, et al. Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages. Arterioscler Thromb Vasc Biol 2006; 26(5): 1169-76.
94. Wiesner P, Choi SH, Almazan F, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor {kappa}B and activator protein-1. Possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010; 107: 56-65.
95. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11(2): 155-61.
96. Leitinger N, Tyner TR, Oslund L, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA 1999; 96(21): 12010-5.
97. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA, Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol 2003; 23(8): 1384-90.
98. Li R, Mouillesseaux KP, Montoya D, et al. Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res 2006; 98(5): 642-50.
99. Bochkov VN. Inflammatory profile of oxidized phospholipids. Thromb Haemost 2007; 97(3): 348-54.
100. Afonyushkin T, Oskolkova OV, Philippova M, et al. Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler Thromb Vasc Biol 2010; 30(5): 1007-13.
101. Yeh M, Cole AL, Choi J, et al. Role for sterol regulatory element binding protein in activation of endothelial cells by phospholipid oxidation products. Circ Res 2004; 95(8): 780-8.
102. Gharavi NM, Alva JA, Mouillesseaux KP, et al. Role of the JAK/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 2007; 282(43): 31460-8.
103. Oskolkova OV, Afonyushkin T, Leitner A, et al. ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response. Blood 2008; 112(2): 330-9.
104. Lee S, Gharavi NM, Honda H, et al. A role for NADPH oxidase 4 in the activation of vascular endothelial cells by oxidized phospholipids. Free Radic Biol Med 2009; 47(2): 145-51.
105. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol 2006; 17(5): 502-9.
106. Itabe H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin Rev Allergy Immunol 2009; 37(1): 4-11.
107. Tsimikas S. Measures of oxidative stress. Clin Lab Med 2006; 26(3): 571-90.
108. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am J Cardiol 2008; 101(10A): 34D-42.
109. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008; 19(4): 369-77.
110. Friedman P, Hörkkö S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: Importance of Schiff base formation and Aldol condensation. J Biol Chem 2001; 277(9): 7010-20.
111. Hõrkkõ S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipidprotein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103(1): 117-28.
112. Itabe H, Takeshima E, Iwasaki H, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269(21): 15274-79.
113. Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996; 76(5): 663-9.
114. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20(3): 698-702.
115. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41(3): 360-70.
116. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003; 278(52): 52841-7.
117. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004; 109(25): 3164-70.
118. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110: 1406-12.
119. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353(1): 46-57.
120. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. J Am Coll Cardiol 2006; 47(9): 1803-10.
121. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006; 47(11): 2219-28.
122. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49(10): 2230-9.
123. Tsimikas S, Mallat Z, Talmud PJ, et al. Elevated oxidized phospholipids on apolipoprotein B-100 particles are associated with future cardiovascular events in the EPIC-Norfolk Study: Potentiation of risk with lipoprotein-associated (Lp-PLA2) and secretory phospholipase A2 (sPLA2) activity. Circulation 2008; AHA abstract Nov 2008.
124. Budoff MJ, Ahmadi N, Gul KM, et al. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med 2009; 49(2-3): 101-7.
125. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009; 119(13): 1711-9.
126. Itabe H, Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 2007; 14(1): 1-11.
127. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 2006; 48(5): 973-9.
128. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51(17): 1653-62.
129. Fraley AE, Schwartz GG, Olsson AG, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Car diol 2009; 53(23): 2186-96.
130. Tsimikas S. High-dose statins prior to percutaneous coronary intervention: a paradigm shift to influence clinical outcomes in the cardiac catheterization laboratory. J Am Coll Cardiol 2009; 54(23): 2164-66.
131. Ahmadi N, Tsimikas S, Hajsadeghi F, et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol 2010; 105(4): 459-66.
132. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2007; 27(8): 1788-95.
133. Arai K, Luke MM, Koschinsky ML, et al. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis 2010; 209(2): 498-503.
134. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a) and risk of fatal and non-fatal coronary events. J Am Coll Cardiol 2010; 56; 946-55.
135. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118(7): 743-53.
136. Burke A, Cresswell N, Kolodgie F, Virmani R, Tsimikas S. Increased expression of oxidation-specific epitopes and Lp(a) reflect unstable plaques in human coronary arteries. J Am Coll Cardiol 2008; 49: A299.
137. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008; 117(25): 3206-15.
138. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions using antibodies against oxidation-specific epitopes. J Am Coll Cardiol 2010; Nov 17. PMID: 21106318.
139. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999; 6: 41-53.
140. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000; 20(3): 689-97.
141. Tsimikas S. Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. Am J Cardiol 2002; 90(3): L22-L27.
142. Shaw PX, Hörkkö S, Tsimikas S, et al. Human-derived antioxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001; 21(8): 1333-9.
143. Aikawa M, Sugiyama S, Hill CC, et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002; 106(11): 1390-6.
144. Torzewski M, Shaw PX, Han KR, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004; 24(12): 2307-12.
145. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071-80.
146. Hartvigsen K, Chou MY, Hansen LF, et al. The role of innate immunity in atherogenesis. J Lipid Res 2009; 50 (Suppl): S388-93.